nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefadroxil—SLC22A8—Conjugated Estrogens—prostate cancer	0.172	0.388	CbGbCtD
Cefadroxil—SLC22A8—Estradiol—prostate cancer	0.151	0.341	CbGbCtD
Cefadroxil—SLC22A6—Conjugated Estrogens—prostate cancer	0.12	0.271	CbGbCtD
Cefadroxil—SLC22A8—urine—prostate cancer	0.01	0.217	CbGeAlD
Cefadroxil—SLC15A1—epithelium—prostate cancer	0.00367	0.0794	CbGeAlD
Cefadroxil—SLC22A8—prostate gland—prostate cancer	0.00359	0.0777	CbGeAlD
Cefadroxil—SLC22A5—Organic cation transport—SLC22A3—prostate cancer	0.00357	0.0732	CbGpPWpGaD
Cefadroxil—SLC15A1—renal system—prostate cancer	0.0034	0.0737	CbGeAlD
Cefadroxil—SLC15A2—prostate gland—prostate cancer	0.00312	0.0676	CbGeAlD
Cefadroxil—SLC22A5—Organic cation transport—SLC22A1—prostate cancer	0.00291	0.0597	CbGpPWpGaD
Cefadroxil—SLC22A5—prostate gland—prostate cancer	0.00272	0.0588	CbGeAlD
Cefadroxil—SLC15A2—seminal vesicle—prostate cancer	0.00264	0.0571	CbGeAlD
Cefadroxil—SLC22A8—renal system—prostate cancer	0.00245	0.053	CbGeAlD
Cefadroxil—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00242	0.0497	CbGpPWpGaD
Cefadroxil—SLC22A5—seminal vesicle—prostate cancer	0.0023	0.0497	CbGeAlD
Cefadroxil—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00219	0.0449	CbGpPWpGaD
Cefadroxil—Cefazolin—PON1—prostate cancer	0.00218	0.436	CrCbGaD
Cefadroxil—SLC15A2—renal system—prostate cancer	0.00213	0.046	CbGeAlD
Cefadroxil—SLC15A2—urethra—prostate cancer	0.00209	0.0452	CbGeAlD
Cefadroxil—SLC22A5—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00197	0.0405	CbGpPWpGaD
Cefadroxil—SLC22A5—renal system—prostate cancer	0.00185	0.04	CbGeAlD
Cefadroxil—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A3—prostate cancer	0.00183	0.0375	CbGpPWpGaD
Cefadroxil—SLC22A5—urethra—prostate cancer	0.00182	0.0393	CbGeAlD
Cefadroxil—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.0018	0.0369	CbGpPWpGaD
Cefadroxil—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00178	0.0366	CbGpPWpGaD
Cefadroxil—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.00167	0.0343	CbGpPWpGaD
Cefadroxil—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A1—prostate cancer	0.00149	0.0306	CbGpPWpGaD
Cefadroxil—SLC15A2—testis—prostate cancer	0.00138	0.0298	CbGeAlD
Cefadroxil—SLC22A5—testis—prostate cancer	0.0012	0.0259	CbGeAlD
Cefadroxil—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.00106	0.0218	CbGpPWpGaD
Cefadroxil—SLC15A2—lymph node—prostate cancer	0.000997	0.0216	CbGeAlD
Cefadroxil—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000984	0.0202	CbGpPWpGaD
Cefadroxil—Cefdinir—MPO—prostate cancer	0.000893	0.178	CrCbGaD
Cefadroxil—Cefaclor—MPO—prostate cancer	0.000885	0.177	CrCbGaD
Cefadroxil—SLC22A5—lymph node—prostate cancer	0.000867	0.0188	CbGeAlD
Cefadroxil—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000752	0.0154	CbGpPWpGaD
Cefadroxil—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.00068	0.014	CbGpPWpGaD
Cefadroxil—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000666	0.0137	CbGpPWpGaD
Cefadroxil—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000666	0.0137	CbGpPWpGaD
Cefadroxil—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000618	0.0127	CbGpPWpGaD
Cefadroxil—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000618	0.0127	CbGpPWpGaD
Cefadroxil—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A1—prostate cancer	0.000568	0.0117	CbGpPWpGaD
Cefadroxil—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000545	0.0112	CbGpPWpGaD
Cefadroxil—Amoxicillin—CYP2C19—prostate cancer	0.000511	0.102	CrCbGaD
Cefadroxil—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000506	0.0104	CbGpPWpGaD
Cefadroxil—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000485	0.00995	CbGpPWpGaD
Cefadroxil—Urticaria—Goserelin—prostate cancer	0.000484	0.00106	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000484	0.00106	CcSEcCtD
Cefadroxil—Anaphylactic shock—Estradiol—prostate cancer	0.000483	0.00106	CcSEcCtD
Cefadroxil—Abdominal pain—Goserelin—prostate cancer	0.000482	0.00106	CcSEcCtD
Cefadroxil—Body temperature increased—Goserelin—prostate cancer	0.000482	0.00106	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Prednisone—prostate cancer	0.000482	0.00106	CcSEcCtD
Cefadroxil—Urticaria—Conjugated Estrogens—prostate cancer	0.00048	0.00105	CcSEcCtD
Cefadroxil—Convulsion—Mitoxantrone—prostate cancer	0.000478	0.00105	CcSEcCtD
Cefadroxil—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000477	0.00105	CcSEcCtD
Cefadroxil—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000477	0.00105	CcSEcCtD
Cefadroxil—Hepatic failure—Epirubicin—prostate cancer	0.000475	0.00104	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000474	0.00972	CbGpPWpGaD
Cefadroxil—Vomiting—Ethinyl Estradiol—prostate cancer	0.000471	0.00103	CcSEcCtD
Cefadroxil—Arthralgia—Mitoxantrone—prostate cancer	0.00047	0.00103	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000469	0.00103	CcSEcCtD
Cefadroxil—Rash—Ethinyl Estradiol—prostate cancer	0.000467	0.00102	CcSEcCtD
Cefadroxil—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000467	0.00102	CcSEcCtD
Cefadroxil—Headache—Ethinyl Estradiol—prostate cancer	0.000464	0.00102	CcSEcCtD
Cefadroxil—Agranulocytosis—Docetaxel—prostate cancer	0.000456	0.000998	CcSEcCtD
Cefadroxil—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.000455	0.000996	CcSEcCtD
Cefadroxil—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000452	0.000991	CcSEcCtD
Cefadroxil—Anaphylactic shock—Mitoxantrone—prostate cancer	0.00045	0.000987	CcSEcCtD
Cefadroxil—Hypersensitivity—Goserelin—prostate cancer	0.000449	0.000985	CcSEcCtD
Cefadroxil—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000445	0.000975	CcSEcCtD
Cefadroxil—Neutropenia—Prednisone—prostate cancer	0.000442	0.000968	CcSEcCtD
Cefadroxil—Muscle spasms—Etoposide—prostate cancer	0.000441	0.000967	CcSEcCtD
Cefadroxil—Agranulocytosis—Capecitabine—prostate cancer	0.000441	0.000967	CcSEcCtD
Cefadroxil—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000441	0.000966	CcSEcCtD
Cefadroxil—Haemoglobin—Docetaxel—prostate cancer	0.00044	0.000965	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Estradiol—prostate cancer	0.00044	0.000965	CcSEcCtD
Cefadroxil—Nausea—Ethinyl Estradiol—prostate cancer	0.00044	0.000965	CcSEcCtD
Cefadroxil—Hepatic failure—Doxorubicin—prostate cancer	0.00044	0.000964	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00044	0.00902	CbGpPWpGaD
Cefadroxil—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000438	0.009	CbGpPWpGaD
Cefadroxil—Haemorrhage—Docetaxel—prostate cancer	0.000438	0.00096	CcSEcCtD
Cefadroxil—Asthenia—Goserelin—prostate cancer	0.000438	0.000959	CcSEcCtD
Cefadroxil—Asthenia—Conjugated Estrogens—prostate cancer	0.000433	0.00095	CcSEcCtD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000432	0.00887	CbGpPWpGaD
Cefadroxil—Pruritus—Goserelin—prostate cancer	0.000431	0.000945	CcSEcCtD
Cefadroxil—Somnolence—Estradiol—prostate cancer	0.00043	0.000942	CcSEcCtD
Cefadroxil—Pruritus—Conjugated Estrogens—prostate cancer	0.000427	0.000937	CcSEcCtD
Cefadroxil—Haemoglobin—Capecitabine—prostate cancer	0.000426	0.000935	CcSEcCtD
Cefadroxil—Dyspepsia—Estradiol—prostate cancer	0.000426	0.000933	CcSEcCtD
Cefadroxil—Haemorrhage—Capecitabine—prostate cancer	0.000424	0.00093	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Estradiol—prostate cancer	0.000417	0.000915	CcSEcCtD
Cefadroxil—Diarrhoea—Goserelin—prostate cancer	0.000417	0.000914	CcSEcCtD
Cefadroxil—Erythema multiforme—Docetaxel—prostate cancer	0.000414	0.000908	CcSEcCtD
Cefadroxil—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000413	0.000906	CcSEcCtD
Cefadroxil—Vertigo—Etoposide—prostate cancer	0.000412	0.000904	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.00041	0.000899	CcSEcCtD
Cefadroxil—Dizziness—Goserelin—prostate cancer	0.000403	0.000884	CcSEcCtD
Cefadroxil—Erythema multiforme—Capecitabine—prostate cancer	0.000401	0.000879	CcSEcCtD
Cefadroxil—Somnolence—Mitoxantrone—prostate cancer	0.0004	0.000878	CcSEcCtD
Cefadroxil—Blood creatinine increased—Epirubicin—prostate cancer	0.0004	0.000877	CcSEcCtD
Cefadroxil—Dizziness—Conjugated Estrogens—prostate cancer	0.000399	0.000875	CcSEcCtD
Cefadroxil—Convulsion—Etoposide—prostate cancer	0.000398	0.000872	CcSEcCtD
Cefadroxil—Dyspepsia—Mitoxantrone—prostate cancer	0.000396	0.000869	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Estradiol—prostate cancer	0.000395	0.000866	CcSEcCtD
Cefadroxil—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000395	0.00811	CbGpPWpGaD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000391	0.00802	CbGpPWpGaD
Cefadroxil—Vomiting—Goserelin—prostate cancer	0.000388	0.00085	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000385	0.000843	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000385	0.000843	CcSEcCtD
Cefadroxil—Rash—Goserelin—prostate cancer	0.000384	0.000843	CcSEcCtD
Cefadroxil—Dermatitis—Goserelin—prostate cancer	0.000384	0.000842	CcSEcCtD
Cefadroxil—Vomiting—Conjugated Estrogens—prostate cancer	0.000384	0.000842	CcSEcCtD
Cefadroxil—Urticaria—Estradiol—prostate cancer	0.000384	0.000842	CcSEcCtD
Cefadroxil—Abdominal pain—Estradiol—prostate cancer	0.000382	0.000837	CcSEcCtD
Cefadroxil—Body temperature increased—Estradiol—prostate cancer	0.000382	0.000837	CcSEcCtD
Cefadroxil—Headache—Goserelin—prostate cancer	0.000382	0.000837	CcSEcCtD
Cefadroxil—Rash—Conjugated Estrogens—prostate cancer	0.000381	0.000835	CcSEcCtD
Cefadroxil—Dermatitis—Conjugated Estrogens—prostate cancer	0.00038	0.000834	CcSEcCtD
Cefadroxil—Haemoglobin—Prednisone—prostate cancer	0.00038	0.000833	CcSEcCtD
Cefadroxil—Headache—Conjugated Estrogens—prostate cancer	0.000378	0.000829	CcSEcCtD
Cefadroxil—Haemorrhage—Prednisone—prostate cancer	0.000378	0.000828	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000377	0.000826	CcSEcCtD
Cefadroxil—Anaphylactic shock—Etoposide—prostate cancer	0.000375	0.000821	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000374	0.00768	CbGpPWpGaD
Cefadroxil—Blood creatinine increased—Doxorubicin—prostate cancer	0.00037	0.000812	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000368	0.000807	CcSEcCtD
Cefadroxil—Thrombocytopenia—Etoposide—prostate cancer	0.000367	0.000804	CcSEcCtD
Cefadroxil—Muscle spasms—Docetaxel—prostate cancer	0.000367	0.000804	CcSEcCtD
Cefadroxil—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A3—prostate cancer	0.000366	0.00751	CbGpPWpGaD
Cefadroxil—Eosinophilia—Epirubicin—prostate cancer	0.000366	0.000801	CcSEcCtD
Cefadroxil—Nausea—Goserelin—prostate cancer	0.000362	0.000794	CcSEcCtD
Cefadroxil—Nausea—Conjugated Estrogens—prostate cancer	0.000359	0.000786	CcSEcCtD
Cefadroxil—Urticaria—Mitoxantrone—prostate cancer	0.000358	0.000784	CcSEcCtD
Cefadroxil—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000357	0.00733	CbGpPWpGaD
Cefadroxil—Hypersensitivity—Estradiol—prostate cancer	0.000356	0.000781	CcSEcCtD
Cefadroxil—Body temperature increased—Mitoxantrone—prostate cancer	0.000356	0.00078	CcSEcCtD
Cefadroxil—Abdominal pain—Mitoxantrone—prostate cancer	0.000356	0.00078	CcSEcCtD
Cefadroxil—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.000356	0.00078	CcSEcCtD
Cefadroxil—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000356	0.00078	CcSEcCtD
Cefadroxil—Muscle spasms—Capecitabine—prostate cancer	0.000355	0.000778	CcSEcCtD
Cefadroxil—Pancytopenia—Epirubicin—prostate cancer	0.000351	0.000769	CcSEcCtD
Cefadroxil—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000349	0.000764	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000348	0.00713	CbGpPWpGaD
Cefadroxil—Asthenia—Estradiol—prostate cancer	0.000347	0.00076	CcSEcCtD
Cefadroxil—Neutropenia—Epirubicin—prostate cancer	0.000345	0.000757	CcSEcCtD
Cefadroxil—Pruritus—Estradiol—prostate cancer	0.000342	0.00075	CcSEcCtD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000342	0.00701	CbGpPWpGaD
Cefadroxil—Eosinophilia—Doxorubicin—prostate cancer	0.000338	0.000741	CcSEcCtD
Cefadroxil—Somnolence—Etoposide—prostate cancer	0.000333	0.00073	CcSEcCtD
Cefadroxil—Vertigo—Capecitabine—prostate cancer	0.000332	0.000727	CcSEcCtD
Cefadroxil—Hypersensitivity—Mitoxantrone—prostate cancer	0.000332	0.000727	CcSEcCtD
Cefadroxil—Diarrhoea—Estradiol—prostate cancer	0.000331	0.000725	CcSEcCtD
Cefadroxil—Convulsion—Docetaxel—prostate cancer	0.000331	0.000724	CcSEcCtD
Cefadroxil—Drowsiness—Epirubicin—prostate cancer	0.000329	0.000722	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000326	0.000715	CcSEcCtD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000326	0.0067	CbGpPWpGaD
Cefadroxil—Arthralgia—Docetaxel—prostate cancer	0.000325	0.000712	CcSEcCtD
Cefadroxil—Cefradine—CYP3A4—prostate cancer	0.000325	0.0649	CrCbGaD
Cefadroxil—Pancytopenia—Doxorubicin—prostate cancer	0.000325	0.000711	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Etoposide—prostate cancer	0.000323	0.000709	CcSEcCtD
Cefadroxil—Asthenia—Mitoxantrone—prostate cancer	0.000323	0.000708	CcSEcCtD
Cefadroxil—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000321	0.00659	CbGpPWpGaD
Cefadroxil—Dizziness—Estradiol—prostate cancer	0.00032	0.000701	CcSEcCtD
Cefadroxil—Neutropenia—Doxorubicin—prostate cancer	0.00032	0.0007	CcSEcCtD
Cefadroxil—Arthralgia—Capecitabine—prostate cancer	0.000314	0.000689	CcSEcCtD
Cefadroxil—Anaphylactic shock—Docetaxel—prostate cancer	0.000311	0.000682	CcSEcCtD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000309	0.00634	CbGpPWpGaD
Cefadroxil—Diarrhoea—Mitoxantrone—prostate cancer	0.000308	0.000675	CcSEcCtD
Cefadroxil—Vomiting—Estradiol—prostate cancer	0.000307	0.000674	CcSEcCtD
Cefadroxil—Agranulocytosis—Epirubicin—prostate cancer	0.000307	0.000673	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Etoposide—prostate cancer	0.000306	0.000671	CcSEcCtD
Cefadroxil—Thrombocytopenia—Docetaxel—prostate cancer	0.000305	0.000668	CcSEcCtD
Cefadroxil—Rash—Estradiol—prostate cancer	0.000305	0.000668	CcSEcCtD
Cefadroxil—Drowsiness—Doxorubicin—prostate cancer	0.000305	0.000668	CcSEcCtD
Cefadroxil—Dermatitis—Estradiol—prostate cancer	0.000305	0.000667	CcSEcCtD
Cefadroxil—Headache—Estradiol—prostate cancer	0.000303	0.000664	CcSEcCtD
Cefadroxil—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000302	0.000662	CcSEcCtD
Cefadroxil—Angioedema—Prednisone—prostate cancer	0.000301	0.000659	CcSEcCtD
Cefadroxil—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—prostate cancer	0.000298	0.00612	CbGpPWpGaD
Cefadroxil—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000298	0.00612	CbGpPWpGaD
Cefadroxil—Urticaria—Etoposide—prostate cancer	0.000298	0.000652	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000297	0.0061	CbGpPWpGaD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000297	0.0061	CbGpPWpGaD
Cefadroxil—Haemoglobin—Epirubicin—prostate cancer	0.000297	0.000651	CcSEcCtD
Cefadroxil—Body temperature increased—Etoposide—prostate cancer	0.000296	0.000649	CcSEcCtD
Cefadroxil—Abdominal pain—Etoposide—prostate cancer	0.000296	0.000649	CcSEcCtD
Cefadroxil—Vertigo—Prednisone—prostate cancer	0.000296	0.000648	CcSEcCtD
Cefadroxil—Haemorrhage—Epirubicin—prostate cancer	0.000296	0.000648	CcSEcCtD
Cefadroxil—Thrombocytopenia—Capecitabine—prostate cancer	0.000295	0.000647	CcSEcCtD
Cefadroxil—Nausea—Estradiol—prostate cancer	0.000287	0.000629	CcSEcCtD
Cefadroxil—Vomiting—Mitoxantrone—prostate cancer	0.000286	0.000628	CcSEcCtD
Cefadroxil—Convulsion—Prednisone—prostate cancer	0.000285	0.000625	CcSEcCtD
Cefadroxil—Agranulocytosis—Doxorubicin—prostate cancer	0.000284	0.000623	CcSEcCtD
Cefadroxil—Rash—Mitoxantrone—prostate cancer	0.000284	0.000622	CcSEcCtD
Cefadroxil—Dermatitis—Mitoxantrone—prostate cancer	0.000284	0.000622	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000284	0.000622	CcSEcCtD
Cefadroxil—Headache—Mitoxantrone—prostate cancer	0.000282	0.000618	CcSEcCtD
Cefadroxil—Arthralgia—Prednisone—prostate cancer	0.00028	0.000614	CcSEcCtD
Cefadroxil—Erythema multiforme—Epirubicin—prostate cancer	0.000279	0.000613	CcSEcCtD
Cefadroxil—Somnolence—Docetaxel—prostate cancer	0.000277	0.000607	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000276	0.00567	CbGpPWpGaD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000276	0.00567	CbGpPWpGaD
Cefadroxil—Hypersensitivity—Etoposide—prostate cancer	0.000276	0.000605	CcSEcCtD
Cefadroxil—Haemoglobin—Doxorubicin—prostate cancer	0.000275	0.000602	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000275	0.000602	CcSEcCtD
Cefadroxil—Dyspepsia—Docetaxel—prostate cancer	0.000274	0.000601	CcSEcCtD
Cefadroxil—Haemorrhage—Doxorubicin—prostate cancer	0.000274	0.000599	CcSEcCtD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000272	0.00557	CbGpPWpGaD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000272	0.00557	CbGpPWpGaD
Cefadroxil—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000269	0.000589	CcSEcCtD
Cefadroxil—Asthenia—Etoposide—prostate cancer	0.000269	0.000589	CcSEcCtD
Cefadroxil—Anaphylactic shock—Prednisone—prostate cancer	0.000269	0.000588	CcSEcCtD
Cefadroxil—Nausea—Mitoxantrone—prostate cancer	0.000268	0.000586	CcSEcCtD
Cefadroxil—Dyspepsia—Capecitabine—prostate cancer	0.000265	0.000582	CcSEcCtD
Cefadroxil—Pruritus—Etoposide—prostate cancer	0.000265	0.000581	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00026	0.00057	CcSEcCtD
Cefadroxil—Erythema multiforme—Doxorubicin—prostate cancer	0.000259	0.000567	CcSEcCtD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000258	0.00529	CbGpPWpGaD
Cefadroxil—Diarrhoea—Etoposide—prostate cancer	0.000256	0.000562	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Docetaxel—prostate cancer	0.000255	0.000558	CcSEcCtD
Cefadroxil—Tension—Epirubicin—prostate cancer	0.000253	0.000553	CcSEcCtD
Cefadroxil—Nervousness—Epirubicin—prostate cancer	0.00025	0.000548	CcSEcCtD
Cefadroxil—Dizziness—Etoposide—prostate cancer	0.000248	0.000543	CcSEcCtD
Cefadroxil—Muscle spasms—Epirubicin—prostate cancer	0.000247	0.000542	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Capecitabine—prostate cancer	0.000247	0.00054	CcSEcCtD
Cefadroxil—Abdominal pain—Docetaxel—prostate cancer	0.000246	0.000539	CcSEcCtD
Cefadroxil—Body temperature increased—Docetaxel—prostate cancer	0.000246	0.000539	CcSEcCtD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000246	0.00504	CbGpPWpGaD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000246	0.00504	CbGpPWpGaD
Cefadroxil—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000245	0.000536	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000241	0.00495	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000241	0.00494	CbGpPWpGaD
Cefadroxil—Urticaria—Capecitabine—prostate cancer	0.000239	0.000525	CcSEcCtD
Cefadroxil—Body temperature increased—Capecitabine—prostate cancer	0.000238	0.000522	CcSEcCtD
Cefadroxil—Abdominal pain—Capecitabine—prostate cancer	0.000238	0.000522	CcSEcCtD
Cefadroxil—Vomiting—Etoposide—prostate cancer	0.000238	0.000522	CcSEcCtD
Cefadroxil—Dyspepsia—Prednisone—prostate cancer	0.000236	0.000518	CcSEcCtD
Cefadroxil—Rash—Etoposide—prostate cancer	0.000236	0.000518	CcSEcCtD
Cefadroxil—Dermatitis—Etoposide—prostate cancer	0.000236	0.000517	CcSEcCtD
Cefadroxil—Headache—Etoposide—prostate cancer	0.000235	0.000514	CcSEcCtD
Cefadroxil—Tension—Doxorubicin—prostate cancer	0.000234	0.000512	CcSEcCtD
Cefadroxil—Nervousness—Doxorubicin—prostate cancer	0.000231	0.000507	CcSEcCtD
Cefadroxil—Vertigo—Epirubicin—prostate cancer	0.000231	0.000507	CcSEcCtD
Cefadroxil—Hypersensitivity—Docetaxel—prostate cancer	0.000229	0.000503	CcSEcCtD
Cefadroxil—Muscle spasms—Doxorubicin—prostate cancer	0.000229	0.000502	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000224	0.0046	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000223	0.00458	CbGpPWpGaD
Cefadroxil—Asthenia—Docetaxel—prostate cancer	0.000223	0.00049	CcSEcCtD
Cefadroxil—Convulsion—Epirubicin—prostate cancer	0.000223	0.000489	CcSEcCtD
Cefadroxil—Nausea—Etoposide—prostate cancer	0.000223	0.000488	CcSEcCtD
Cefadroxil—Hypersensitivity—Capecitabine—prostate cancer	0.000222	0.000487	CcSEcCtD
Cefadroxil—Pruritus—Docetaxel—prostate cancer	0.00022	0.000483	CcSEcCtD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00022	0.00452	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00022	0.00451	CbGpPWpGaD
Cefadroxil—Gastrointestinal pain—Prednisone—prostate cancer	0.00022	0.000481	CcSEcCtD
Cefadroxil—Arthralgia—Epirubicin—prostate cancer	0.000219	0.00048	CcSEcCtD
Cefadroxil—Asthenia—Capecitabine—prostate cancer	0.000216	0.000474	CcSEcCtD
Cefadroxil—Vertigo—Doxorubicin—prostate cancer	0.000214	0.000469	CcSEcCtD
Cefadroxil—Urticaria—Prednisone—prostate cancer	0.000213	0.000468	CcSEcCtD
Cefadroxil—Pruritus—Capecitabine—prostate cancer	0.000213	0.000467	CcSEcCtD
Cefadroxil—Diarrhoea—Docetaxel—prostate cancer	0.000213	0.000467	CcSEcCtD
Cefadroxil—Abdominal pain—Prednisone—prostate cancer	0.000212	0.000465	CcSEcCtD
Cefadroxil—Body temperature increased—Prednisone—prostate cancer	0.000212	0.000465	CcSEcCtD
Cefadroxil—Cephalexin—CYP3A4—prostate cancer	0.00021	0.042	CrCbGaD
Cefadroxil—Anaphylactic shock—Epirubicin—prostate cancer	0.00021	0.00046	CcSEcCtD
Cefadroxil—Convulsion—Doxorubicin—prostate cancer	0.000206	0.000452	CcSEcCtD
Cefadroxil—Diarrhoea—Capecitabine—prostate cancer	0.000206	0.000452	CcSEcCtD
Cefadroxil—Dizziness—Docetaxel—prostate cancer	0.000206	0.000451	CcSEcCtD
Cefadroxil—Thrombocytopenia—Epirubicin—prostate cancer	0.000206	0.000451	CcSEcCtD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000205	0.00421	CbGpPWpGaD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000205	0.00421	CbGpPWpGaD
Cefadroxil—Arthralgia—Doxorubicin—prostate cancer	0.000203	0.000444	CcSEcCtD
Cefadroxil—Dizziness—Capecitabine—prostate cancer	0.000199	0.000437	CcSEcCtD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000199	0.00409	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000199	0.00408	CbGpPWpGaD
Cefadroxil—Vomiting—Docetaxel—prostate cancer	0.000198	0.000434	CcSEcCtD
Cefadroxil—Hypersensitivity—Prednisone—prostate cancer	0.000198	0.000434	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000197	0.00404	CbGpPWpGaD
Cefadroxil—Rash—Docetaxel—prostate cancer	0.000196	0.00043	CcSEcCtD
Cefadroxil—Dermatitis—Docetaxel—prostate cancer	0.000196	0.00043	CcSEcCtD
Cefadroxil—Headache—Docetaxel—prostate cancer	0.000195	0.000427	CcSEcCtD
Cefadroxil—Anaphylactic shock—Doxorubicin—prostate cancer	0.000194	0.000426	CcSEcCtD
Cefadroxil—Asthenia—Prednisone—prostate cancer	0.000193	0.000422	CcSEcCtD
Cefadroxil—Vomiting—Capecitabine—prostate cancer	0.000192	0.00042	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000191	0.000419	CcSEcCtD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.00019	0.00391	CbGpPWpGaD
Cefadroxil—Thrombocytopenia—Doxorubicin—prostate cancer	0.00019	0.000417	CcSEcCtD
Cefadroxil—Rash—Capecitabine—prostate cancer	0.00019	0.000417	CcSEcCtD
Cefadroxil—Pruritus—Prednisone—prostate cancer	0.00019	0.000416	CcSEcCtD
Cefadroxil—Dermatitis—Capecitabine—prostate cancer	0.00019	0.000416	CcSEcCtD
Cefadroxil—Headache—Capecitabine—prostate cancer	0.000189	0.000414	CcSEcCtD
Cefadroxil—Somnolence—Epirubicin—prostate cancer	0.000187	0.000409	CcSEcCtD
Cefadroxil—Nausea—Docetaxel—prostate cancer	0.000185	0.000405	CcSEcCtD
Cefadroxil—Dyspepsia—Epirubicin—prostate cancer	0.000185	0.000405	CcSEcCtD
Cefadroxil—Diarrhoea—Prednisone—prostate cancer	0.000184	0.000403	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000183	0.00375	CbGpPWpGaD
Cefadroxil—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000181	0.000397	CcSEcCtD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.00018	0.00368	CbGpPWpGaD
Cefadroxil—Nausea—Capecitabine—prostate cancer	0.000179	0.000392	CcSEcCtD
Cefadroxil—Dizziness—Prednisone—prostate cancer	0.000178	0.000389	CcSEcCtD
Cefadroxil—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000177	0.000388	CcSEcCtD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000177	0.00362	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000174	0.00356	CbGpPWpGaD
Cefadroxil—Somnolence—Doxorubicin—prostate cancer	0.000173	0.000379	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Epirubicin—prostate cancer	0.000172	0.000376	CcSEcCtD
Cefadroxil—Dyspepsia—Doxorubicin—prostate cancer	0.000171	0.000375	CcSEcCtD
Cefadroxil—Vomiting—Prednisone—prostate cancer	0.000171	0.000374	CcSEcCtD
Cefadroxil—Rash—Prednisone—prostate cancer	0.000169	0.000371	CcSEcCtD
Cefadroxil—Dermatitis—Prednisone—prostate cancer	0.000169	0.000371	CcSEcCtD
Cefadroxil—Headache—Prednisone—prostate cancer	0.000168	0.000369	CcSEcCtD
Cefadroxil—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000168	0.000368	CcSEcCtD
Cefadroxil—Urticaria—Epirubicin—prostate cancer	0.000167	0.000366	CcSEcCtD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000166	0.00341	CbGpPWpGaD
Cefadroxil—Abdominal pain—Epirubicin—prostate cancer	0.000166	0.000364	CcSEcCtD
Cefadroxil—Body temperature increased—Epirubicin—prostate cancer	0.000166	0.000364	CcSEcCtD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000166	0.0034	CbGpPWpGaD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000162	0.00333	CbGpPWpGaD
Cefadroxil—Nausea—Prednisone—prostate cancer	0.000159	0.00035	CcSEcCtD
Cefadroxil—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000159	0.000348	CcSEcCtD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000157	0.00322	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000155	0.00318	CbGpPWpGaD
Cefadroxil—Hypersensitivity—Epirubicin—prostate cancer	0.000155	0.000339	CcSEcCtD
Cefadroxil—Urticaria—Doxorubicin—prostate cancer	0.000154	0.000338	CcSEcCtD
Cefadroxil—Body temperature increased—Doxorubicin—prostate cancer	0.000154	0.000337	CcSEcCtD
Cefadroxil—Abdominal pain—Doxorubicin—prostate cancer	0.000154	0.000337	CcSEcCtD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000151	0.0031	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000151	0.0031	CbGpPWpGaD
Cefadroxil—Asthenia—Epirubicin—prostate cancer	0.000151	0.00033	CcSEcCtD
Cefadroxil—Pruritus—Epirubicin—prostate cancer	0.000149	0.000326	CcSEcCtD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000144	0.00295	CbGpPWpGaD
Cefadroxil—Diarrhoea—Epirubicin—prostate cancer	0.000144	0.000315	CcSEcCtD
Cefadroxil—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000143	0.00294	CbGpPWpGaD
Cefadroxil—Hypersensitivity—Doxorubicin—prostate cancer	0.000143	0.000314	CcSEcCtD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000142	0.00291	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.00014	0.00288	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.00014	0.00288	CbGpPWpGaD
Cefadroxil—Asthenia—Doxorubicin—prostate cancer	0.000139	0.000306	CcSEcCtD
Cefadroxil—Dizziness—Epirubicin—prostate cancer	0.000139	0.000304	CcSEcCtD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000138	0.00283	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000138	0.00283	CbGpPWpGaD
Cefadroxil—Pruritus—Doxorubicin—prostate cancer	0.000137	0.000301	CcSEcCtD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000136	0.00278	CbGpPWpGaD
Cefadroxil—Vomiting—Epirubicin—prostate cancer	0.000134	0.000293	CcSEcCtD
Cefadroxil—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000133	0.00273	CbGpPWpGaD
Cefadroxil—Diarrhoea—Doxorubicin—prostate cancer	0.000133	0.000291	CcSEcCtD
Cefadroxil—Rash—Epirubicin—prostate cancer	0.000132	0.00029	CcSEcCtD
Cefadroxil—Dermatitis—Epirubicin—prostate cancer	0.000132	0.00029	CcSEcCtD
Cefadroxil—Headache—Epirubicin—prostate cancer	0.000132	0.000288	CcSEcCtD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.000131	0.00269	CbGpPWpGaD
Cefadroxil—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000131	0.00269	CbGpPWpGaD
Cefadroxil—Dizziness—Doxorubicin—prostate cancer	0.000128	0.000282	CcSEcCtD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000128	0.00263	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000125	0.00256	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000125	0.00256	CbGpPWpGaD
Cefadroxil—Nausea—Epirubicin—prostate cancer	0.000125	0.000273	CcSEcCtD
Cefadroxil—Vomiting—Doxorubicin—prostate cancer	0.000124	0.000271	CcSEcCtD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000123	0.00252	CbGpPWpGaD
Cefadroxil—Rash—Doxorubicin—prostate cancer	0.000123	0.000269	CcSEcCtD
Cefadroxil—Dermatitis—Doxorubicin—prostate cancer	0.000122	0.000268	CcSEcCtD
Cefadroxil—Headache—Doxorubicin—prostate cancer	0.000122	0.000267	CcSEcCtD
Cefadroxil—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000118	0.00243	CbGpPWpGaD
Cefadroxil—Nausea—Doxorubicin—prostate cancer	0.000115	0.000253	CcSEcCtD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000114	0.00234	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000113	0.00232	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000112	0.0023	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000107	0.00219	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000105	0.00216	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000104	0.00214	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000104	0.00214	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000103	0.00212	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000101	0.00208	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.0001	0.00205	CbGpPWpGaD
Cefadroxil—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	9.89e-05	0.00203	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	9.51e-05	0.00195	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—ABCG5—prostate cancer	9.34e-05	0.00192	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	9.28e-05	0.0019	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC22A1—prostate cancer	9.12e-05	0.00187	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	8.82e-05	0.00181	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—GNG5—prostate cancer	8.68e-05	0.00178	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC22A3—prostate cancer	8.45e-05	0.00173	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC22A1—prostate cancer	8.25e-05	0.00169	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	8.11e-05	0.00166	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—GNG5—prostate cancer	7.85e-05	0.00161	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—ABCG5—prostate cancer	7.8e-05	0.0016	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	7.64e-05	0.00157	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.52e-05	0.00154	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.4e-05	0.00152	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	7.29e-05	0.0015	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	7.09e-05	0.00146	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.98e-05	0.00143	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC22A1—prostate cancer	6.89e-05	0.00141	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.77e-05	0.00139	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—PRKACB—prostate cancer	6.69e-05	0.00137	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.66e-05	0.00137	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—GNG5—prostate cancer	6.55e-05	0.00134	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	6.44e-05	0.00132	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.31e-05	0.00129	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	6.13e-05	0.00126	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.02e-05	0.00124	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.98e-05	0.00123	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.88e-05	0.00121	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	5.69e-05	0.00117	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—RXRA—prostate cancer	5.59e-05	0.00115	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—PRKACB—prostate cancer	5.58e-05	0.00115	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.32e-05	0.00109	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.27e-05	0.00108	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—RXRA—prostate cancer	5.06e-05	0.00104	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.02e-05	0.00103	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	4.68e-05	0.00096	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.44e-05	0.000911	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	4.34e-05	0.000891	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—PPARA—prostate cancer	4.27e-05	0.000877	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—RXRA—prostate cancer	4.22e-05	0.000866	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—PPARA—prostate cancer	3.86e-05	0.000793	CbGpPWpGaD
Cefadroxil—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.72e-05	0.000763	CbGpPWpGaD
Cefadroxil—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.45e-05	0.000708	CbGpPWpGaD
Cefadroxil—SLC22A5—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.39e-05	0.000696	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—PPARA—prostate cancer	3.22e-05	0.000662	CbGpPWpGaD
Cefadroxil—SLC22A8—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.07e-05	0.00063	CbGpPWpGaD
Cefadroxil—SLC22A6—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.56e-05	0.000525	CbGpPWpGaD
